Gut Peptides and Other Regulators in Obesity

Matthew T. Scharf; Rexford S. Ahima

doi:10.1055/s-2004-860863

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2004; 24(4): 335-347
DOI: 10.1055/s-2004-860863

Gut Peptides and Other Regulators in Obesity

Matthew T. Scharf¹ , Rexford S. Ahima¹ ^, ²

¹University of Pennsylvania School of Medicine, Division of Endocrinology, Diabetes and Metabolism; and the Neuroscience Graduate Group, Philadelphia, Pennsylvania
²Assistant Professor of Medicine; Director of the Weight Management & Metabolism Program, Presbyterian Medical Center, Philadelphia, Pennsylvania

Abstract

ABSTRACT

Obesity has reached epidemic levels in industrialized countries and is increasing worldwide. This trend has serious public health consequences, since obesity increases the risk of diabetes, hypertension, heart disease, sleep apnea, cancer, arthritis, cholelithiasis, fatty liver disease, and other complications. Obesity is the result of an imbalance between energy intake and expenditure; hence, an understanding of how gastrointestinal function is integrated with the hormonal regulation of energy balance is pertinent to the pathophysiology of obesity. Nutrients, peptides, and neural afferents from the gut influence the size and frequency of meals and satiety. The long-term regulation of energy stores is mediated primarily through the actions of adiposity hormones, such as leptin and insulin, in the hypothalamus and other neuronal circuits in the brain. Efforts are underway to determine how these peripheral and central pathways may be targeted for treatment of obesity and related diseases.

KEYWORDS

Gastrointestinal system - peptides - nutrients - obesity - adipose tissue - leptin - adiponectin - cytokines

Full Text

References

REFERENCES

1 Hedley A A, Ogden C L, Johnson C L, Carroll M D, Curtin L R, Flegal K M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004; 291 2847-2850
2 Ogden C L, Flegal K M, Carroll M D, Johnson C L. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002; 288 1728-1732
3 Kopelman P G. Obesity as a medical problem. Nature. 2000; 404 635-643
4 Calle E E, Thun M J, Petrelli J M, Rodriguez C, Heath Jr C W. Body-mass index and mortality in a prospective cohort of U. S. adults. N Engl J Med. 1999; 341 1097-1105
5 Ahima R S, Flier J S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000; 11 327-332
6 Unger R H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144 5159-5165
7 Barsh G S, Farooqi I S, O'Rahilly S. Genetics of body-weight regulation. Nature. 2000; 404 644-651
8 Zimmet P, Alberti K G, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414 782-787
9 Kennedy G C. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci. 1953; 140 578-596
10 Harris R B, Martin R J. Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol. 1984; 247 R380-R386
11 Hervey G R. The effects of lesions in the hypothalamus in parabiotic rats. J Physiol. 1959; 145 336-352
12 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372 425-432 , Erratum in: Nature. 1995; 374 479
13 Chen H, Charlat O, Tartaglia L A et al.. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996; 84 491-495
14 Flier J S. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004; 116 337-350
15 Elmquist J K, Elias C F, Saper C B. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999; 22 221-232
16 Ahima R S, Osei S Y. Molecular regulation of eating behavior: new insights and prospects for therapeutic strategies. Trends Mol Med. 2001; 7 205-213
17 Mayer J. Glucostatic mechanism of regulation of food intake. N Engl J Med. 1953; 249 13-16
18 Thompson D A, Campbell R G. Hunger in humans induced by 2-deoxy-D-glucose: glucoprivic control of taste preference and food intake. Science. 1977; 198 1065-1068
19 Oomura Y, Ono T, Ooyama H, Wayner M J. Glucose and osmosensitive neurones of the rat hypothalamus. Nature. 1969; 222 282-284
20 Bergen H T, Monkman N, Mobbs C V. Injection with gold thioglucose impairs sensitivity to glucose: evidence that glucose-responsive neurons are important for long-term regulation of body weight. Brain Res. 1996; 734 332-336
21 Novin D, VanderWeele D A, Rezek M. Infusion of 2-deoxy-D-glucose into the hepatic-portal system causes eating: evidence for peripheral glucoreceptors. Science. 1973; 181 858-860
22 Bray G A. Amino acids, protein, and body weight. Obes Res. 1997; 5 373-376
23 Fernstrom J D, Wurtman R J. Brain serotonin content: physiological dependence on plasma tryptophan levels. Science. 1971; 173 149-152
24 Kasser T R, Harris R B, Martin R J. Level of satiety: fatty acid and glucose metabolism in three brain sites associated with feeding. Am J Physiol. 1985; 248 R447-R452
25 Sergeyev V, Broberger C, Gorbatyuk O, Hokfelt T. Effect of 2-mercaptoacetate and 2-deoxy-D-glucose administration on the expression of NPY, AGRP, POMC, MCH and hypocretin/orexin in the rat hypothalamus. Neuroreport. 2000; 11 117-121
26 Friedman M I, Harris R B, Ji H, Ramirez I, Tordoff M G. Fatty acid oxidation affects food intake by altering hepatic energy status. Am J Physiol. 1999; 276 R1046-R1053
27 Nagase H, Bray G A, York D A. Effects of pyruvate and lactate on food intake in rat strains sensitive and resistant to dietary obesity. Physiol Behav. 1996; 59 555-560
28 Tso P, Liu M, Kalogeris T J. The role of apolipoprotein A-IV in food intake regulation. J Nutr. 1999; 129 150-156
29 Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab. 2001; 12 118-122
30 Tschop M, Smiley D L, Heiman M L. Ghrelin induces adiposity in rodents. Nature. 2000; 407 908-913
31 Cummings D E, Weigle D S, Frayo R S et al.. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002; 346 1623-1630
32 Holdstock C, Engstrom B E, Ohrvall M, Lind L, Sundbom M, Karlsson F A. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab. 2003; 88 3177-3183
33 Cowley M A, Smith R G, Diano S et al.. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003; 37 649-661
34 Chen H Y, Trumbauer M E, Chen A S et al.. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004; 145 2607-2612
35 Sun Y, Ahmed S, Smith R G. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol. 2003; 23 7973-7981
36 Sun Y, Wang P, Zheng H, Smith R G. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA. 2004; 101 4679-4684
37 Smith G P, Gibbs J. Satiating effect of cholecystokinin. Ann N Y Acad Sci. 1994; 713 236-241
38 Moran T H, Katz L F, Plata-Salaman C R, Schwartz G J. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol. 1998; 274 R618-R625
39 Kopin A S, Mathes W F, McBride E W et al.. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest. 1999; 103 383-391 , Erratum in: J Clin Invest 1999;103:759
40 Berglund M M, Hipskind P A, Gehlert D R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes [review]. Exp Biol Med (Maywood). 2003; 228 217-244
41 Batterham R L, Cowley M A, Small C J et al.. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002; 418 650-654
42 Batterham R L, Cohen M A, Ellis S M et al.. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003; 349 941-948
43 Tschop M, Castaneda T R, Joost H G et al.. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?. Nature. 2004; 430 165-167 , Erratum in Nature. 2004; 431 1038 , Withcomb, DC [corrected to Whitcomb, DC]
44 Clark J T, Sahu A, Kalra P S, Balasubramaniam A, Kalra S P. Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept. 1987; 17 31-39
45 Stanley B G, Daniel D R, Chin A S, Leibowitz S F. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides. 1985; 6 1205-1211
46 Kanatani A, Mashiko S, Murai N et al.. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology. 2000; 141 1011-1016
47 Jia B Q, Taylor I L. Failure of pancreatic polypeptide release in congenitally obese mice. Gastroenterology. 1984; 87 338-343
48 Asakawa A, Inui A, Yuzuriha H et al.. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003; 124 1325-1336
49 Ueno N, Inui A, Iwamoto M et al.. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology. 1999; 117 1427-1432
50 Batterham R L, Le Roux C W, Cohen M A et al.. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003; 88 3989-3992
51 Berntson G G, Zipf W B, O'Dorisio T M, Hoffman J A, Chance R E. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides. 1993; 14 497-503
52 Holst J J. Glucagon-like Peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab. 1999; 10 229-235
53 Verdich C, Flint A, Gutzwiller J P et al.. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001; 86 4382-4389
54 Nauck M A, Kleine N, Orskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia. 1993; 36 741-744
55 Turton M D, O'Shea D, Gunn I et al.. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996; 379 69-72
56 Drucker D J, Lovshin J, Baggio L et al.. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Ann N Y Acad Sci. 2000; 921 226-232
57 Scrocchi L A, Hill M E, Saleh J, Perkins B, Drucker D J. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes. 2000; 49 1552-1560
58 Tang-Christensen M, Larsen P J, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 2000; 6 802-807
59 Dakin C L, Gunn I, Small C J et al.. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001; 142 4244-4250
60 Baggio L L, Huang Q, Brown T J, Drucker D J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004; 127 546-558
61 Cohen M A, Ellis S M, Le Roux C W et al.. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003; 88 4696-4701
62 Meier J J, Nauck M A, Schmidt W E, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept. 2002; 107 1-13
63 Gault V A, Flatt P R, O'Harte F P. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun. 2003; 308 207-213
64 Gault V A, O'Harte F P, Flatt P R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides. 2003; 37 253-263
65 Miyawaki K, Yamada Y, Ban N et al.. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002; 8 738-742
66 Yamada K, Wada E, Santo-Yamada Y, Wada K. Bombesin and its family of peptides: prospects for the treatment of obesity. Eur J Pharmacol. 2002; 440 281-290
67 Gutzwiller J P, Drewe J, Hildebrand P, Rossi L, Lauper J Z, Beglinger C. Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology. 1994; 106 1168-1173
68 Ohki-Hamazaki H, Watase K, Yamamoto K et al.. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature. 1997; 390 165-169
69 Hoppener J W, Ahren B, Lips C J. Islet amyloid and type 2 diabetes mellitus. N Engl J Med. 2000; 343 411-419
70 Reda T K, Geliebter A, Pi-Sunyer F X. Amylin, food intake, and obesity. Obes Res. 2002; 10 1087-1091
71 Erlanson-Albertsson C, York D. Enterostatin-a peptide regulating fat intake. Obes Res. 1997; 5 360-372
72 Lin L, York D A. Amygdala enterostatin induces c-Fos expression in regions of hypothalamus that innervate the PVN. Brain Res. 2004; 1020 147-153
73 Ahima R S, Flier J S. Leptin. Annu Rev Physiol. 2000; 62 413-437
74 Coleman D L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978; 14 141-148
75 Flier J S. Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab. 1998; 83 1407-1413
76 Erickson J C, Hollopeter G, Palmiter R D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science. 1996; 274 1704-1707
77 Segal-Lieberman G, Bradley R L, Kokkotou E et al.. Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc Natl Acad Sci U S A. 2003; 100 10085-10090
78 Ahima R, Osei S Y. Leptin and appetite control in lipodystrophy. J Clin Endocrinol Metab. 2004; 89 4254-4257
79 Howard J K, Cave B J, Oksanen L J, Tzameli I, Bjorback C, Flier J S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med. 2004; 10 734-738
80 Mori H, Hanada R, Hanada T et al.. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med. 2004; 10 739-743
81 Zabolotny J M, Bence-Hanulec K K, Stricker-Krongrad A et al.. PTP1B regulates leptin signal transduction in vivo. Dev Cell. 2002; 2 489-495
82 Cheng A, Uetani N, Simoncic P D et al.. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002; 2 497-503
83 Schwartz M W, Figlewicz D P, Baskin D G, Woods S C, Porte Jr D. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev. 1992; 13 387-414
84 Benoit S C, Air E L, Coolen L M et al.. The catabolic action of insulin in the brain is mediated by melanocortins. J Neurosci. 2002; 22 9048-9052
85 Bruning J C, Gautam D, Burks D J et al.. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000; 289 2122-2125
86 Niswender K D, Morrison C D, Clegg D J et al.. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes. 2003; 52 227-231
87 Niswender K D, Schwartz M W. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol. 2003; 24 1-10
88 Berg A H, Combs T P, Scherer P E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002; 13 84-89
89 Maeda N, Shimomura I, Kishida K et al.. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8 731-737
90 Kubota N, Terauchi Y, Yamauchi T et al.. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277 25863-25866
91 Yamauchi T, Kamon J, Minokoshi Y et al.. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8 1288-1295
92 Goldstein B J, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004; 89 2563-2568
93 Yamauchi T, Kamon J, Ito Y et al.. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423 762-769
94 Hug C, Wang J, Ahmad N S, Gogan J S, Tsao T S, Lodish H F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004; 101 10308-10313
95 Steppan C M, Lazar M A. The current biology of resistin. J Intern Med. 2004; 255 439-447
96 Rajala M W, Qi Y, Patel H R et al.. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 2004; 53 1671-1679
97 Steppan C M, Bailey S T, Bhat S et al.. The hormone resistin links obesity to diabetes. Nature. 2001; 409 307-312
98 Rajala M W, Obici S, Scherer P E, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003; 111 225-230
99 Banerjee R R, Rangwala S M, Shapiro J S et al.. Regulation of fasted blood glucose by resistin. Science. 2004; 303 1195-1198
100 Wellen K E, Hotamisligil G S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003; 112 1785-1788
101 Moller D E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000; 11 212-217
102 Wallenius V, Wallenius K, Ahren B et al.. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002; 8 75-79

Rexford S AhimaM.D. Ph.D.

University of Pennsylvania School of Medicine, Division of Endocrinology, Diabetes and Metabolism

764 Clinical Research Building, 415 Curie Blvd

Philadelphia, PA 19104

Email: ahima@mail.med.upenn.edu